Full text is available at the source.
Abstract
This systematic review and meta-analysis evaluated cancer outcomes among adults with type 2 diabetes using glucagon-like peptide-1 receptor agonists (GLP-1RAs).
- GLP-1RAs may influence cancer outcomes in patients with type 2 diabetes mellitus (T2DM).
- The analysis assessed both overall cancer incidence and site-specific cancer types.
- Uncertainty exists regarding the specific biological mechanisms by which GLP-1RAs could affect tumor development.
Simplified